Researchers have identified an antioxidant in locally grown black tea leaves as a potential inhibitor of protease activity in SARS-CoV-2, the virus that causes COVID-19, Chiayi Chang Gung Memorial Hospital said on Wednesday.
A research team led by Wu Ching-yuan (吳清源), head of the hospital’s Department of Traditional Chinese Medicine, used a computer program to identify potential antiviral components in traditional plants, the hospital said in a statement.
Theaflavin, a polyphenolic compound, shows broad-spectrum antiviral activity against several viruses and could be used as a lead compound for the development of a SARS-CoV-2 inhibitor to target the DNA-directed ribonucleic acid (RNA) polymerase (RdRp) enzyme.
Photo copied by Lin I-chang, Taipei Times
In coronaviruses, RdRp catalyzes the replication of RNA from a template, making it an attractive candidate to help develop a treatment, Wu said.
RdRp in SARS-CoV-2 is also a primary target for the antiviral remdesivir, which the WHO has called the most promising drug available for the treatment of COVID-19, he said.
Remdesivir works by inhibiting RdRp, which many RNA viruses — including coronaviruses — use to replicate themselves.
The antiviral effects of theaflavin are similar to those of remdesivir, Wu said.
However, the exact in vivo effect is still unclear, and further research is needed to confirm the mechanism whereby theaflavin targets SARS-CoV-2, Wu said.
The findings were published by the American Society for Microbiology in the Journal of Medical Virology on March 13, the hospital said.
In other news, the Central Epidemic Command Center (CECC) on Thursday said that quinoline antimalarial drugs, which have been discussed as a possible treatment for COVID-19, are produced in Taiwan and could be made available if testing proves them to be effective against the novel coronavirus.
In a small French study, doctors used a drug in the quinoline family — hydroxychloroquine — to reduce the duration and severity of COVID-19 symptoms in people with mild cases, said Chang Shan-chwen (張上淳), convener of the center’s expert advisory panel.
If properly tested and approved, a process that normally takes 12 to 18 months, the drug could conceivably reduce the burden on medical resources such as quarantine facilities, Chang said.
Minister of Health and Welfare Chen Shih-chung (陳時中), who heads the CECC, said that there is one manufacturer of quinoline drugs in Taiwan.
If the treatment were proved to be viable, the government’s first priority would be to guarantee domestic supply, Chen said.
The government could participate in the distribution of the drug on the precondition of not harming the manufacturer’s commercial interests, Chen said.
Internationally, drug distribution rights could be used diplomatically to build ties with international partners to address shortages amid the pandemic, he said.
Drugs that have been touted as potentially effective against COVID-19 have become the subject of heated competition in the past few weeks as governments scramble to combat the disease.
Remdesivir is being used on a trial basis in Taiwan and has reduced fevers in the three COVID-19 patients who have been treated with it, although its effect on overall recovery time is still being studied, Chang said.
CAUTION: Based on intelligence from the nation’s security agencies, MOFA has cautioned Taiwanese travelers about heightened safety risks in China-friendly countries The Ministry of Foreign Affairs (MOFA) yesterday urged Taiwanese to be aware of their safety when traveling abroad, especially in countries that are friendly to China. China in June last year issued 22 guidelines that allow its courts to try in absentia and sentence to death so-called “diehard” Taiwanese independence activists, even though Chinese courts have no jurisdiction in Taiwan. Late last month, a senior Chinese official gave closed-door instructions to state security units to implement the guidelines in countries friendly to China, a government memo and a senior Taiwan security official said, based on information gathered by Taiwan’s intelligence agency. The
The National Immigration Agency (NIA) said yesterday that it will revoke the dependent-based residence permit of a Chinese social media influencer who reportedly “openly advocated for [China’s] unification through military force” with Taiwan. The Chinese national, identified by her surname Liu (劉), will have her residence permit revoked in accordance with Article 14 of the “Measures for the permission of family- based residence, long-term residence and settlement of people from the Mainland Area in the Taiwan Area,” the NIA said in a news release. The agency explained it received reports that Liu made “unifying Taiwan through military force” statements on her online
Taiwan Semiconductor Manufacturing Co (TSMC), the world’s largest contract chipmaker, said yesterday that it is looking to hire 8,000 people this year, at a time when the tech giant is expanding production capacity to maintain its lead over competitors. To attract talent, TSMC would launch a large-scale recruitment campaign on campuses across Taiwan, where a newly recruited engineer with a master’s degree could expect to receive an average salary of NT$2.2 million (US$60,912), which is much higher than the 2023 national average of NT$709,000 for those in the same category, according to government statistics. TSMC, which accounted for more than 60 percent
Tung Tzu-hsien (童子賢), a Taiwanese businessman and deputy convener of the nation’s National Climate Change Committee, said yesterday that “electrical power is national power” and nuclear energy is “very important to Taiwan.” Tung made the remarks, suggesting that his views do not align with the country’s current official policy of phasing out nuclear energy, at a forum organized by the Taiwan People’s Party titled “Challenges and Prospects of Taiwan’s AI Industry and Energy Policy.” “Taiwan is currently pursuing industries with high added- value and is developing vigorously, and this all requires electricity,” said the chairman
RSS